On Friday, Shares of Pepco Holdings, Inc. (NYSE:POM), lost -0.11% to $26.38.
Headline of release should read: Pepco Holdings Declared Third Quarter Dividend (instead of Pepco Holdings Declared Second Quarter Dividend).
PEPCO HOLDINGS DECLARES THIRD QUARTER DIVIDEND
Pepco Holdings Inc. (POM) declared Thursday that its board of directors declared a quarterly dividend of $0.27 per share on Pepco Holdings’ common stock that is payable on Sept. 30, 2015, to shareholders of record on Sept. 10, 2015, assuming the company’s projected merger with Exelon Corporation does not close on or preceding to the close of business on Sept. 10, 2015.
Pepco Holdings, Inc., through its auxiliaries, engages in the transmission, distribution, and supply of electricity. The company also distributes and supplies natural gas. In addition, the company designs, constructs, and operates energy projects and distributed generation equipment, counting combined heat and power plants principally for federal, state, and local government customers.
Shares of NTELOS Holdings Corp (NASDAQ:NTLS), inclined 7.55% to $5.84, during its last trading session.
NTELOS Holdings, will hold a conference call at 11:00 a.m. ET on Tuesday, July 28, 2015 to talk about its second quarter 2015 financial results.
NTELOS Holdings Corp., through its auxiliaries, provides digital wireless communications services. The company offers wireless voice and digital data personal communication products and services primarily to retail and business customers under the NTELOS Wireless and FRAWG Wireless brands.
At the end of Friday’s trade, Shares of Genetic Technologies Limited (ADR) (NASDAQ:GENE), lost -1.75% to $3.36.
Genetic Technologies Limited, declared that underpinned by a strong balance sheet, following the successful capital raise in March 2015, the Company has launched an initiative to reinvigorate the pathway to Peer Review Publication. Attaining such publications in medical journals will assist to strengthen the Company’s commercial position and accelerate reimbursement talk aboutions with private payers. In addition, the Company plans to conduct three U.S. clinical studies and is presently in the process of preparing for the presentation of recently accomplished scientific validation studies.
The Company had formerly conducted multiple scientific studies to develop and validate the first generation BREVAGen test in addition to created two health economic models to demonstrate potential cost savings and health benefits associated with the BREVAGen test. Importantly, due to the nature of the technology and the specific improvements incorporated in BREVAGenplus, the research undertaken and published based on the original version of the test remains applicable to the new iteration.
Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of genetic tests for breast and ovarian cancer, bowel and uterine cancer, and prostate cancer; neurogenetic diagnostic assays; and gene testing for Epilepsy SCN1A gene related disorders.
Finally, Sensata Technologies Holding N.V. (NYSE:ST), ended its last trade with -1.13% loss, and closed at $49.70.
Sensata Technologies Holding N.V., will issue a press release announcing its financial results for the second quarter ended June 30, 2015 on Tuesday, July 28, 2015.
Sensata Technologies Holding N.V., through its auxiliaries, develops, manufactures, and sells sensors and controls. It operates in two segments, Sensors and Controls. The Sensors segment manufactures pressure, temperature, speed, position, and force sensors, in addition to electromechanical sensors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
